Psymion

• Antidepressants
• Adrenergic Uptake Inhibitors
• ATC:N06AA21

• Deprilept
• Ludiomil
• Maprotilina [Inn-Spanish]
• Maprotiline Hcl
• Maprotiline [Usan:Ban:Inn]
• Maprotilinum [Inn-Latin]
• Maprotylina
• Maprotylina [Polish]
• Psymion

• No information avaliable

C₂₀H₂₃N

No information avaliable

Psymion MSDS

M. Wilhelm, et al. Helv. Chim. Acta. 52, 1385 (1969)

277.403 g/mol

93 ^oC

Slightly soluble

Solid

5.546

Tablet (10, 25, 50, and 75mg film coated)

For treatment of depression, including the depressed phase of bipolar depression, psychotic depression, and involutional melancholia, and may also be helpful in treating certain patients suffering severe depressive neurosis.

Maprotiline is a tetracyclic antidepressant. Although its main therapeutic use is in the treatment of depression, it has also been shown to exert a sedative effect on the anxiety component that often accompanies depression. In one sleep study, it was shown that maprotiline increases the duration of the REM sleep phase in depressed patients, compared to imipramine which reduced the REM sleep phase. Maprotiline is a strong inhibitor of noradrenaline re-uptake in the brain and peripheral tissues, however it is worthy to note that it is a weak inhibitor of serotonergic uptake. In addition, it displays strong antihistaminic action (which may explain its sedative effects) as well as weak anticholinergic action. Maprotiline also has lower alpha adrenergic blocking activity than amitriptyline.

Completely absorbed following oral administration

LD₅₀=~900 mg/kg (Orally in rats); LD₅₀=90 mg/kg (Orally in women); Signs of overdose include motor unrest, muscular twitching and rigidity, tremor, ataxia, convulsions, hyperpyrexia, vertigo, mydriasis, vomiting, cyanosis, hypotension, shock, tachycardia, cardiac arrhythmias, impaired cardiac conduction, respiratory depression, and disturbances of consciousness up to deep coma.

No information avaliable

Humans and other mammals